Merck & Co Inc

MRK

108.170USD

-1.010-0.93%

Close 01/23, 16:00（ET）Quotes delayed by 15 min

Merck & Co Inc's Score

Industry at a Glance

Industry Ranking

21 / 159

Overall Ranking

83 / 4546

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

50°C



Very Low

Very High

Positive

Merck & Co Inc Highlights

StrengthsRisks

Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 64.17B.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 46.40%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 46.40%.

Fairly Valued

The company’s latest PE is 14.41, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.99B shares, decreasing 2.62% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 51.41K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.02.

Analyst Rating

Based on 30 analysts

Buy

Current Rating

114.047

Target Price

+4.20%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Merck & Co Inc is 9.03, ranking 20 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 17.28B, representing a year-over-year increase of 3.72%, while its net profit experienced a year-over-year increase of 83.24%.

Score

Industry at a Glance

Previous score

9.03

Change

0



Financials

7.11

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.77

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

9.26

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Merck & Co Inc is 8.17, ranking 28 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is 14.41, which is 6264.84% below the recent high of 917.15 and 26.03% above the recent low of 10.66.

Score

Industry at a Glance

Previous score

8.17

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 21/159

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Merck & Co Inc is 7.67, ranking 97 out of 159 in the Pharmaceuticals industry. The average price target is 102.50, with a high of 139.00 and a low of 82.00.

Score

Industry at a Glance

Previous score

7.67

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Merck & Co Inc is 7.27, ranking 68 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 113.28 and the support level at 104.70, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.21

Change

-1.94

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-01-22

The current institutional shareholding score of Merck & Co Inc is 7.00, ranking 44 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 80.28%, representing a quarter-over-quarter decrease of 1.32%. The largest institutional shareholder is The Vanguard, holding a total of 250.94M shares, representing 10.11% of shares outstanding, with 0.99% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

250.94M

-0.32%

BlackRock Institutional Trust Company, N.A.

141.15M

-1.15%

State Street Investment Management (US)

118.18M

-0.26%

Wellington Management Company, LLP

75.28M

-2.05%

Geode Capital Management, L.L.C.

59.80M

+1.44%

Charles Schwab Investment Management, Inc.

53.70M

-0.31%

Norges Bank Investment Management (NBIM)

36.11M

+3.23%

Fidelity Management & Research Company LLC

27.61M

-3.04%

Fisher Investments

Star Investors

24.07M

-3.78%

BlackRock Asset Management Ireland Limited

22.50M

-1.24%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Merck & Co Inc is 9.20, ranking 13 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.28. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Merck & Co Inc’s latest ESG disclosure is at an average level in the Pharmaceuticals industry, showing no material impact on overall risk.

Merck & Co Inc

MRK

8.09 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Gilead Sciences Inc

GILD

8.87 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Mirum Pharmaceuticals Inc

MIRM

8.80 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Prestige Consumer Healthcare Inc

PBH

8.76 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Catalyst Pharmaceuticals Inc

CPRX

8.74 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

ANI Pharmaceuticals Inc

ANIP

8.73 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment